Basic Study
Copyright
©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 28, 2018; 24(44): 5013-5024
Published online Nov 28, 2018. doi: 10.3748/wjg.v24.i44.5013
Table 1 Clinical materials used in this article
No .Sex Age Lymph nodes TNM Pathology Differentiation MSI Organ 1 M 67 5 (14) T4aN2aM0 Adenocarcinoma Moderate No Rectum 2 M 53 0 (22) T2N0M0 Adenocarcinoma Moderate - Rectum 3 M 72 4 (20) T4aN2aM0 Adenocarcinoma Poor - Right colon 4 M 52 0 (16) T3N0M0 Adenocarcinoma Moderate - Rectum 5 M 52 3 (25) T3N1bM0 Adenocarcinoma Moderate - Sigmoid colon 6 F 57 0 (15) T4aN0M0 Adenocarcinoma Moderate - Left colon 7 F 51 0 (14) T4aN0M0 Adenocarcinoma Moderate No Rectum 8 F 66 19 (27) T3N2bM0 Adenocarcinoma Poor No Rectum 9 F 71 0 (16) T4bN0M1b Adenocarcinoma Moderate No Rectum
Table 2 Details of the four CpG regions in the CpG islands of formin 2
Target TSS Start End Length Target strand Distance2TSS FMN2_1 240255184 240255353 240255531 179 + 169 FMN2_2 240255184 240255809 240256007 199 + 625 FMN2_3 240255184 240256241 240256483 243 + 1057 FMN2_4 240255184 240256757 240257017 261 + 1573
Table 3 Primers used for the MethylTarget™ assays
Primer name Primer FMN2_1_F GAGGGTYGGGATGGTTTGAG FMN2_1_R CCCCCRCTCCCCTTCTTT FMN2_2F GAGTGTGYGGATTTTTTTGAGGT FMN2_2R AAATATCTAAAAACAAATCCTCTTACTCC FMN2_3F GATTTGTTYGAGAGTTTGGTTGT FMN2_3R AAACRCATCCTCAAAAACATCCT FMN2_4F TTTTTGAGTYGAGGGTTTAGAATTG FMN2_4R CACRTTCTAAAAACCATCCRCAAC
Table 4 Methylation level of each CG site in the CpG island regions
Target Position Type P value (t -test)OR (L95-U95) (logistic) C mean N mean FMN2_1 25 CG 0.007774578 2.1731 (0.9323-5.0653) 0.17 0.04 FMN2_1 27 CG 0.01061292 1.5266 (0.8980-2.5953) 0.16 0.03 FMN2_1 30 CG 0.1359111 1.3535 (0.7970-2.2986) 0.15 0.03 FMN2_1 32 CG 0.01875771 1.7416 (0.8662-3.5016) 0.16 0.04 FMN2_1 35 CG 0.03998355 1.2722 (0.8959-1.8068) 0.18 0.05 FMN2_1 38 CG 0.01419169 1.6993 (0.8462-3.4125) 0.16 0.03 FMN2_1 46 CG 0.003990128 2.2454 (0.9140-5.5161) 0.15 0.02 FMN2_1 90 CG 0.1134924 1.3103 (0.6401-2.6825) 0.16 0.03 FMN2_1 108 CG 0.06252571 1.2532 (0.7873-1.9948) 0.17 0.04 FMN2_1 114 CG 0.1134924 1.1858 (0.8641-1.6273) 0.18 0.05 FMN2_1 117 CG 0.05030852 1.3499 (0.8867-2.0550) 0.19 0.04 FMN2_1 123 CG 0.01061292 2.2247 (0.9162-5.4017) 0.16 0.03 FMN2_1 126 CG 0.09391197 1.2852 (0.7471-2.2110) 0.16 0.03 FMN2_1 134 CG 0.01875771 2.4645 (0.6195-9.8050) 0.16 0.02 FMN2_2 27 CG 0.000493624 1.3442 (1.0433-1.7321) 0.28 0.07 FMN2_2 51 CG 0.01419169 1.2762 (0.9670-1.6843) 0.17 0.04 FMN2_2 63 CG 0.007774578 1.4062 (0.9872-2.0030) 0.37 0.25 FMN2_2 70 CG 0.000781571 1.3753 (1.0378-1.8226) 0.24 0.05 FMN2_2 74 CG 0.000493624 1.3079 (1.0283-1.6636) 0.31 0.07 FMN2_2 78 CG 0.000287947 1.3676 (1.0603-1.7639) 0.25 0.05 FMN2_2 81 CG 0.00185109 1.3630 (0.9664-1.9224) 0.21 0.05 FMN2_2 107 CG 0.000493624 1.3025 (0.9942-1.7063) 0.24 0.06 FMN2_2 131 CG 0.007774578 1.2706 (0.9662-1.6708) 0.15 0.03 FMN2_2 137 CG 0.002756067 1.3002 (0.9986-1.6928) 0.21 0.05 FMN2_2 143 CG 0.00123406 1.3743 (1.0297-1.8341) 0.20 0.04 FMN2_2 164 CG 0.000287947 1.3527 (1.0108-1.8101) 0.29 0.07 FMN2_2 170 CG 0.00123406 1.2431 (1.0019-1.5424) 0.28 0.08 FMN2_3 24 CG 0.005635541 1.3854 (0.9994-1.9207) 0.20 0.05 FMN2_3 31 CG 0.005635541 1.4241 (0.9731-2.0841) 0.23 0.04 FMN2_3 47 CG 0.002756067 1.3776 (0.9695-1.9574) 0.24 0.06 FMN2_3 50 CG 0.003990128 1.3787 (1.0219-1.8599) 0.22 0.05 FMN2_3 57 CG 0.00123406 1.3592 (1.0212-1.8091) 0.25 0.06 FMN2_3 60 CG 0.003990128 1.5630 (0.9433-2.5897) 0.19 0.04 FMN2_3 68 CG 0.00185109 1.3474 (1.0273-1.7673) 0.23 0.06 FMN2_3 75 CG 0.00123406 1.3787 (0.9962-1.9082) 0.26 0.06 FMN2_3 80 CG 0.00123406 1.3582 (0.9518-1.9380) 0.24 0.05 FMN2_3 92 CG 0.00185109 1.3665 (0.9746-1.9159) 0.23 0.05 FMN2_3 98 CG 0.00123406 1.3200 (0.9414-1.8509) 0.27 0.06 FMN2_3 105 CG 0.000781571 1.4801 (0.9296-2.3566) 0.22 0.04 FMN2_3 107 CG 0.007774578 1.2402 (1.0141-1.5168) 0.21 0.05 FMN2_3 119 CG 0.00123406 1.4326 (0.9810-2.0921) 0.19 0.04 FMN2_3 131 CG 0.000493624 1.7790 (0.9589-3.3006) 0.22 0.04 FMN2_3 147 CG 0.007774578 1.3343 (0.9443-1.8856) 0.20 0.04 FMN2_3 153 CG 0.000493624 1.5405 (0.9677-2.4523) 0.22 0.05 FMN2_3 158 CG 8.23E-05 1.9417 (0.8981-4.1979) 0.31 0.08 FMN2_3 170 CG 4.11E-05 1714240.0000 (0.0000-Inf) 0.32 0.08 FMN2_3 174 CG 4.11E-05 11577516733.0000 (0.0000-Inf) 0.34 0.08 FMN2_3 183 CG 0.000287947 1.6836 (0.9224-3.0731) 0.28 0.06 FMN2_3 187 CG 0.000287947 1.4526 (0.9861-2.1399) 0.27 0.06 FMN2_3 203 CG 0.000781571 1.4980 (0.9815-2.2861) 0.25 0.05 FMN2_4 36 CG 0.003990128 1.1409 (1.0248-1.2702) 0.41 0.14 FMN2_4 42 CG 0.002756067 1.2068 (1.0353-1.4068) 0.38 0.12 FMN2_4 47 CG 0.000781571 1.2264 (1.0309-1.4589) 0.37 0.10 FMN2_4 61 CG 0.005386639 1.1552 (1.0206-1.3075) 0.38 0.10 FMN2_4 66 CG 0.0003108 243.9222 (0.0000-Inf) 0.40 0.09 FMN2_4 69 CG 8.23E-05 1.7294 (0.6520-4.5874) 0.42 0.09 FMN2_4 72 CG 0.003990128 1.2209 (1.0296-1.4477) 0.4 0.13 FMN2_4 80 CG 4.11E-05 2515571.0000 (0.0000-Inf) 0.48 0.18 FMN2_4 84 CG 0.00185109 1.2366 (1.0241-1.4931) 0.39 0.12 FMN2_4 94 CG 0.002756067 1.2121 (1.0363-1.4178) 0.38 0.12 FMN2_4 98 CG 0.003990128 1.1618 (1.0236-1.3186) 0.36 0.11 FMN2_4 110 CG 0.00185109 1.1712 (1.0253-1.3378) 0.44 0.19 FMN2_4 123 CG 0.000781571 1.2218 (1.0321-1.4463) 0.40 0.10 FMN2_4 127 CG 0.00185109 1.2220 (1.0324-1.4464) 0.39 0.11 FMN2_4 131 CG 8.23E-05 1.3179 (1.0259-1.6931) 0.38 0.08 FMN2_4 136 CG 0.003990128 1.1979 (1.0209-1.4054) 0.34 0.09 FMN2_4 150 CG 4.11E-05 1217702.0000 (0.0000-Inf) 0.54 0.22 FMN2_4 152 CG 0.003990128 1.1644 (1.0196-1.3297) 0.39 0.12 FMN2_4 166 CG 0.000164541 1.3446 (0.9896-1.8269) 0.45 0.16 FMN2_4 168 CG 0.001710676 1.2557 (1.0089-1.5628) 0.44 0.16 FMN2_4 176 CG 4.11E-05 26059.6300 (0.0000-Inf) 0.52 0.21 FMN2_4 186 CG 0.000781571 1.1735 (1.0224-1.3469) 0.54 0.2 FMN2_4 189 CG 0.003990128 1.1348 (1.0221-1.2600) 0.49 0.18 FMN2_4 213 CG 0.00185109 1.1572 (1.0241-1.3076) 0.47 0.14 FMN2_4 221 CG 0.002756067 1.1534 (1.0276-1.2947) 0.45 0.13 FMN2_4 234 CG 0.00185109 1.1981 (1.0181-1.4099) 0.32 0.08 FMN2_4 236 CG 0.000493624 1.2631 (1.0149-1.5720) 0.36 0.08
Table 5 Relationship between formin 2 methylation levels and clinicopathological data
Factor No .FMN2 P valueLow, n (%) High, n (%) Age (yr) < 60 136 66 (45.83) 70 (28.69) 0.00061 ≥ 60 252 78 (54.17) 174 (71.31) Gender Male 210 72 (50.00) 138 (56.56) 0.2105 Female 178 72 (50.00) 106 (43.44) Height (cm) < 170 138 52 (48.60) 86 (47.25) 0.8250 ≥ 170 151 55 (51.40) 96 (52.75) Weight (kg) < 80 156 56 (49.12) 100 (51.55) 0.6812 ≥ 80 152 58 (50.88) 94 (48.45) T T1 11 5 (3.47) 6 (2.47) 0.4830 T2 54 16 (11.11) 38 (15.71) T3 270 106 (73.61) 164 (67.77) T4 51 17 (11.81) 34 (14.05) N N0 212 69 (47.92) 143 (59.34) 0.02931 N1 + N2 173 75 (52.08) 98 (40.66) M M0 264 98 (80.33) 166 (85.13) 0.2651 M1 53 24 (19.67) 29 (14.87) Stage I + II 197 62 (45.26) 135 (58.19) 0.01611 III + IV 172 75 (54.74) 97 (41.81) Lymphovascular invasion Yes 231 77 (60.63) 154 (72.99) 0.01801 No 107 50 (39.37) 57 (27.01) Vascular invasion Yes 78 31 (24.80) 47 (22.71) 0.6627 No 254 94 (75.20) 160 (77.29) Perineural invasion Yes 59 20 (24.39) 39 (26.53) 0.7225 No 170 62 (75.61) 108 (73.47) Tumor status Tumor-free 246 86 (71.07) 160 (77.29) 0.2094 Tumor-present 82 35 (28.93) 47 (22.71) KRAS mutation Yes 28 8 (42.11) 20 (54.05) 0.3972 No 28 11 (57.89) 17 (45.95)